Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | AMD1 | P17707 | 2/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6572765 | 1.00 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL6572874 | 0.73 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL6572871 | 0.73 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL6573859 | 0.71 | ADORA3 (0.46) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6573865 | 0.71 | ADORA3 (0.46) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13239669 | 0.70 | SLC29A1 (0.42) | RXFP1SLC29A1 | |
| SCHEMBL13239670 | 0.68 | SLC29A1 (0.64) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL13265449 | 0.68 | SLC29A1 (0.64) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL13265429 | 0.68 | SLC29A1 (0.54) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL13265430 | 0.67 | ADORA2A (0.39) | RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1090019-B1 | ADENOSINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| EP-1447407-A1 | Adenosine derivatives | GLAXO GROUP LIMITED (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-6677316-B2 | TREATING ISCHEMIA, CARDIOVASCULAR DISORDERS, STROKE, PAIN, NERVOUS SYSTEM DISORDERS OR SLEEP APNEA; ADENOSINE A1 RECEPTOR AGONIST; 2-(3-(TERT-BUTYL)-1,2,4-OXADIAZOL-5-YL)-5-(6-(ISOBUTYLAMINO)-9H-PURIN-9-YL) TETRAHYDROFURAN-3,4-DIOL | SMITHKLINE BEECHAM CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030096788-A1 | Adenosine derivatives | GLAXO WELLCOME INC. | 2003-05-22 | — | — | US | disclosed |
| US-6492348-B1 | Adenosine derivatives | SMITHKLINE BEECHAM CORPORATION | 2002-12-10 | — | — | US | disclosed |
| EP-1090019-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067262-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096788-A1 | Adenosine derivatives | ADORA3, ADORA2A, ADORA1 | PI4KA 1727/4885PI4K2B 2708/4885PI4K2A 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.